LongANABSep 2026
AnaptysBio, Inc.
AnaptysBio's value is heavily tied to royalties from GSK's Jemperli, which has grown into a strategically important oncology asset with more than $1 billion of sales. Greenhaven…
ANAB
Which hedge funds are long ANAB?
1 published idea on AnaptysBio, Inc. across 1 fund — 1 long and 0 short.
Each entry below comes from a hedge fund's own investor letter, not a 13F filing, so it carries the reasoning behind the position on AnaptysBio, Inc.: the full thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.